Biotech Topline Data Releases 2027: 6 Examples Compared

A biotech topline data release should lead with the pre-specified primary endpoint result, name the analysis population behind each number, report safety with discontinuation counts, and state the next step. Six releases from Lilly, Novo Nordisk, Summit Therapeutics, Cassava Sciences, Pfizer and Viking Therapeutics show how each choice reads, including the releases with mixed or bad news.

Last updated: November 14, 2026. Figures are as reported by the companies and outlets linked. This is an analysis of public releases, not legal or regulatory advice.

Contents

• Six releases compared

• Which result to lead with

• Mixed Phase 3 results

• Failed trials and stopped programs

• What a release should include

• Frequently asked questions

How do six biotech topline releases compare?

Six releases from 2024 and 2025 show five different ways to word a clinical readout: two positive, one superior but below expectations, one mixed, one failed and one program stopped. The table shows what each led with and where the caveat sat.

ReleaseDateResult typeWhat the release led withWhere the caveat sat

Lilly, orforglipron ACHIEVE-1April 17, 2025Positive Phase 3Statistically significant efficacy and a safety profile consistent with the drug classA second analysis and footnotes in the same release Novo Nordisk, CagriSema REDEFINE 1December 20, 2024Superior, below expectationsSuperiority and 22.7% weight lossA lower 20.4% figure and the 57% top-dose share in the body Viking, VK2735 VENTUREFebruary 27, 2024Positive Phase 214.7% from baseline and 13.1% placebo-adjusted, side by sideDiscontinuation table and one related serious adverse event Summit, ivonescimab HARMONiMay 30, 2025Mixed Phase 3Progression-free survival met, overall survival a positive trendNo statistical significance on overall survival, with the FDA requirement noted Cassava, simufilam RETHINK-ALZNovember 25, 2024Failed Phase 3The headline: data did not meet co-primary endpointsNone needed, the headline states it Pfizer, danuglipronApril 14, 2025Program stoppedDecision to discontinue developmentLiver injury case and 1,400-participant safety context follow

Which result should a topline release lead with?

A topline release should lead with the result on the pre-specified primary endpoint and say which analysis population produced each number. Three releases show why that label matters.

Lilly gave both analyses in one release

Eli Lilly announced positive Phase 3 results for its oral GLP-1 pill orforglipron on April 17, 2025. On the efficacy estimand, which assumes participants stayed on treatment, A1C fell 1.3% to 1.6% from a baseline of 8.0% across 559 participants, and weight fell 7.9% at the highest dose. The same release reported the treatment-regimen estimand, A1C reductions of 1.2% to 1.5% against 0.4% for placebo, and noted that some body weight endpoints for the 3 mg dose were not controlled for type 1 error. Discontinuations due to adverse events were 6%, 4% and 8% across doses against 1% for placebo, as TipRanks reported from the release.

Novo Nordisk led with the number that assumed adherence

Novo Nordisk reported on December 20, 2024 that CagriSema produced 22.7% weight loss at 68 weeks in the REDEFINE 1 trial, against 16.1% for semaglutide alone and 2.3% for placebo. That figure assumed all participants adhered to treatment, and only 57% reached the highest dose. Pharmaphorum's report gave the treatment-policy figure as 20.4%, said the result fell short of the 25% weight loss the market had wanted, and said Novo shares fell 20.7% that day. Coverage then led with the lower figure, so the second number reached readers anyway.

Viking showed raw and placebo-adjusted figures

Viking Therapeutics reported on February 27, 2024 that its Phase 2 VENTURE trial of VK2735 in 176 adults produced weight loss of up to 14.7% from baseline after 13 weeks, or 13.1% adjusted for placebo. The release also said up to 88% of patients lost at least 10% of body weight against 4% on placebo. The release text disclosed that 13% of VK2735 patients stopped treatment early against 14% on placebo, and that one patient had a serious adverse event of dehydration judged related to the drug.

How do companies word a mixed Phase 3 result?

A company announcing a mixed Phase 3 result has to separate the endpoint that was met from the one that was not, and the Summit Therapeutics release of May 30, 2025 shows the tension. In the HARMONi trial of ivonescimab in EGFR-mutated lung cancer, Summit reported a statistically significant and clinically meaningful improvement in progression-free survival, with a hazard ratio of 0.52.

On overall survival, the other primary endpoint, Summit described a positive trend. The hazard ratio was 0.79 and the p-value 0.057, which did not reach statistical significance, as a later Summit release restated with a 95% confidence interval of 0.62 to 1.01. Investing.com reported that the FDA had indicated a statistically significant overall survival benefit is needed for approval, and that Summit said it would weigh the timing of its filing.

The wording drew scrutiny. Fierce Biotech quoted Eric Schmidt, an analyst at Cantor Fitzgerald, as saying the release reported the best possible outcome on consistency between the Asian and Western patient groups. The practical lesson is that the phrase "positive trend" sits next to a p-value above 0.05, so it should travel with the number and the regulatory consequence.

How do companies word a failed trial or a stopped program?

Companies word a failed trial most credibly when the headline says the endpoints were missed and the same release states the next step. Two releases from 2024 and 2025 did this in different ways.

Cassava stated the failure in the headline

Cassava Sciences titled its November 25, 2024 release "Topline Phase 3 Data Did Not Meet Co-Primary Endpoints." The first paragraph said the ReThink-ALZ study of simufilam in Alzheimer's disease missed its co-primary, secondary and exploratory biomarker endpoints. Chief executive Rick Barry announced the same day that the second Phase 3 trial, ReFocus-ALZ, would be discontinued. When the company reported the second trial on March 25, 2025, Barry called the results unambiguous and said Cassava would end simufilam development for Alzheimer's disease.

Pfizer paired a stop decision with its safety context

Pfizer's April 14, 2025 update announced it was discontinuing danuglipron, its oral GLP-1 candidate for weight management. It was a development update, not a topline readout. The release said one asymptomatic participant had potential drug-induced liver injury that resolved after treatment stopped, that liver enzyme elevations across more than 1,400 participants were in line with approved drugs in the class, and that Pfizer would continue an oral GIPR antagonist. Chris Boshoff, Pfizer's chief scientific officer, said the company was disappointed to discontinue the molecule.

What should a biotech topline release include?

A biotech topline release should contain six elements that a reporter or analyst can check without calling the company. The six releases above each included some of them, and none included every one.

• State in the first sentence whether the pre-specified primary endpoint was met.

• Label the analysis population beside each number, such as efficacy estimand or treatment policy, and from baseline or placebo-adjusted.

• Show the comparator result next to the treatment result.

• Report adverse events with discontinuation counts and any serious event judged related to the drug.

• Give the regulatory consequence when it is known, as Summit did for the FDA.

• Name the next step and its timing, as Cassava did for its second trial.

Each draft should pass medical, legal and regulatory review before release. The guides to FDA communications for biotech, clinical-stage biotech PR and Regulation FD cover the review steps, and medical congress PR covers readouts tied to a meeting. For hiring support, see the best biotech PR agencies, the biotech PR cost guide and the healthcare PR agency page. The same habit of labeling every number appears in the AI product claims study.

A release holds up when a reporter can find the second number without asking for it.

Frequently asked questions

What is a topline data release?

A topline data release is a company announcement of the first headline results from a clinical trial, usually before full data are analyzed or presented at a medical meeting. It typically reports the primary endpoint, key secondary endpoints and a safety summary.

What are the efficacy and treatment-policy estimands?

The efficacy estimand estimates the effect if all participants stayed on treatment, while the treatment-policy estimand estimates the effect regardless of whether they did. Lilly and Novo Nordisk both reported the two figures, and the efficacy figure is the higher one in both releases.

Should a release report a non-significant result?

A topline release should report it with its hazard ratio or effect size and its p-value, and state that it was not statistically significant. Summit did this for overall survival in HARMONi, with a p-value of 0.057.

Does a failed trial need a separate press release?

A failed pivotal trial generally needs its own announcement, because the result is material to investors and patients. Cassava announced its ReThink-ALZ failure, and the decision to stop a second trial, in a single release.

Who should review a topline release before it goes out?

Medical, legal, regulatory and investor relations teams should review a topline release before it goes out. Public companies also need a plan for filing the release so that all investors receive it at the same time.